Evidence review: 27 October 2026. A joint WHO regional release dated 5 October 2026 reports that Asia-Pacific countries have made progress in planning against antimicrobial resistance (AMR), but implementation financing remains inadequate. The analysis draws on national reporting from 28 countries across WHO’s South-East Asia and Western Pacific regions. These are regional figures—not India-only estimates and not a judgment of any particular hospital.
What the WHO data actually show
| Indicator | Reported finding | Why it matters |
|---|---|---|
| Countries reporting data | 28 | Regional progress can be compared but national circumstances differ. |
| Countries with an endorsed multisectoral AMR action plan | 27 of 28 | Having a plan does not guarantee implementation. |
| Countries reporting over 70% of antibiotic use from WHO’s Access group | 9 countries (33%) | Supports efforts toward appropriate antibiotic selection and surveillance. |
| Countries reporting more than 75% of healthcare facilities with basic WASH services | 16 of 28 (57%) | Water, sanitation and hygiene prevent infection before antibiotics are needed. |
WHO also reported that only eight countries financed their AMR activities entirely from domestic sources, while 15 countries obtained less than 30% of AMR funding domestically. National action plans require staffing, laboratory capacity, medicines governance, monitoring and reliable financing.
WHO AWaRe classification: Access, Watch and Reserve
The Access group includes effective first- or second-choice antibiotics for many common infections; Watch agents have greater stewardship priority; Reserve agents are generally for selected difficult-to-treat infections. AWaRe does not replace a patient-specific diagnosis, local antibiogram, microbiology result, allergy history, renal function or guideline-based selection. A broad-spectrum agent may be clinically appropriate in severe infection, and an Access agent may be inappropriate if there is no bacterial indication.
Six actions for a district hospital or CHC
- Document the indication: record working diagnosis, severity, suspected focus, selected agent, route and expected review date.
- Obtain cultures when indicated: collect appropriate samples before antibiotics where feasible, without delaying time-critical sepsis management.
- Review at 48–72 hours: reassess clinical response, culture results, need for ongoing antibiotics, de-escalation and IV-to-oral switch.
- Audit avoidable broad-spectrum use: review unnecessary combination therapy, duplicate anaerobic coverage, prolonged prophylaxis and use for likely viral syndromes.
- Strengthen infection prevention: hand hygiene, cleaning, sterilisation, device care, safe water and vaccination reduce infection burden.
- Use local data: local microbiology and district antibiograms are more actionable than assuming a regional resistance percentage applies to a specific patient.
Suggested one-month quality-improvement audit
Sample systemic antibiotic prescriptions and calculate the proportion with (a) a documented clinical indication and (b) a documented 48–72-hour review. Define numerator, denominator, exceptions and sampling method before starting. This is a suggested local audit, not a WHO-mandated national target. Review findings with the pharmacy, microbiology, nursing and clinical teams; focus on feedback rather than blame.
What the report does not establish
The regional figures do not prove that 67% of antibiotics prescribed in India are inappropriate, nor do they define a single antibiotic protocol for all facilities. Appropriate prescribing requires diagnosis, patient factors, local resistance patterns and stewardship systems.
Official references
Professional education and quality improvement; antibiotic selection must follow patient assessment, local guidance and available susceptibility data.